Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
Ambulatory Intravenous InotropicSupport in Pediatric and Congenital
Heart Failure: How to Evaluate Outcomes
Sotiria Apostolopoulou
Department of Paediatric Cardiology and Adult Congenital Heart Disease
Onassis Cardiac Surgery Centre, Athens, Greece
Background
• CHD and CM cause end-stage HF in children and adults CHD patients
frequently requiring inotropes and MCS as a bridge to transplant in up
to 57% of cases
• Children on MCS, even for a short time, have:
- survival rates to transplant or recovery as low as 75%
- risk for thromboembolic, hemorrhagic, neurologic events, respiratory
failure and multisystem organ failure
• In the absence of heart transplantation, end-stage HF has significant
morbidity and mortality, poor quality of life, complicated management,
and frequently, long-term continuous inotropic support in the ICU
• Post myocarditis dilated CM, even if needing inotropic or MCS, has a
significant chance of recovery within 2 years → should these patients
receive long-term inotropic support prior to referral for transplant?
Ambulatory inotropic therapy in end-stage HF in adults
• AI therapy is advocated in stage D HF for 1) pts awaiting heart
transplant or MCS or 2) palliative care in non eligible pts
• Older studies showed that home inotropic therapy in adults, despite
improving clinical status and lowering cost, increases mortality and
morbidity probably related to arrhythmic events•
• Low dose PO enoximone is safe but does not improve mortality,
cardiovascular hospitalization or 6MWTD
• 112 inotrope dependent pts (not transplant candidates)
- median F/U: 130 days (2-2345 days)
- High mortality (76%), rehospitalization 49%
• Trend towards MCS with the significant risks of thromboembolic
events, bleeding, cerebral hemorrhage, pump malfunction, etc
ACCF/AHA guideline for the management of heart failure JACC 2013
ESSENTIAL trials. Metra et al. Eur Heart J 2009
Gorodeski et al. Circ Heart Fail 2009
Packer et al. N Engl J Med 1991
Hampton et al. Lancet 1997
Cohn et al. N Engl J Med 1998
Park et al. Circ Heart Fail 2012
Experience with ambulatory inotropic therapy in children with end-stage HF
• 14 pts on home IV milrinone and/or dobutamine, age 6-18 yrs
- Duration 14-476 (median 68) days
- 8 palliative care, 6 awaiting heart transplant
- Safe, cost, family dynamics with hospitalization
• 7 pts on home IV inotropes, age 14.6 ±3.7 yrs
- Duration 4-84 (median10) wks
- 1 death, 5 complications in 2 pts, 6 pts bridged to transplant
- EF from 30 to 39% on therapy
• 106 pts on home IV inotropes, age 10.1±6.4yrs
- Duration median 47 days (4–323 days)
- 85% transplant
- 8% weaned from support
- 6% deaths
Berg et al. J Heart Lung Transplant 2007
Price et al. J Card Fail 2006
Birnbaum et al. Circ Heart Fail 2015
Criteria for IV ambulatory inotropes (AI) and/or Levosimendan (LS)
• Intractable CHF despite maximum oral therapy
• Cause: myocarditis, dilated CM, restrictive CM, CHD
• Inability to wean IV inotropes after multiple attempts of slow weans over at least 4 weeks
• Stabilization on IV inotropes without need for ICU
• Without significant arrhythmia–Defibrillator if indicated
• Local Transplant Team → negative for mechanical assist device, mostly due to age and size
Apostolopoulou SC, et al. Pediatr Cardiol. 2018 Oct;39(7):1315-1322
Protocol for ambulatory inotropes
• Maximal tolerated oral therapy, including β-blockers, diuretics
and ACE inhibitors along with the IV inotropes
• Subsequent initiation of levosimendan infusions q 2-3 wks
• Stable in hospital for at least 4 weeks
• Insertion of central Hickman catheter
• Education of 2 caretakers (incl. the pt if >12 yo) in sterile
procedures, infusion preparation, pump function etc
• Patients stay locally for 2 additional weeks
• Periodic attempt at slow wean of inotropes
Apostolopoulou SC, et al. Pediatr Cardiol. 2018 Oct;39(7):1315-1322
Population Demographics
Characteristics No (%)
Patients 27
Gender
Male 16 (59%)
Female 11 (41%)
Age at initiation of therapy 9.4 (0.1-26.1) years
NYHA Class at initiation of therapy III-IV
NT- proBNP at initiation of therapy 2542 (320-16166) pg/ml
Inotropic therapy
Ambulatory Inotropes alone 7 (26%)
Levosimendan alone 6 (22%)
Combined Ambulatory Inotropes and Levosimendan 14 (52%)
Apostolopoulou SC, et al. Pediatr Cardiol. 2018 Oct;39(7):1315-1322
Diagnosis No (%)
Myocarditis 6 (22%)
Dilated cardiomyopathy 13 (48%)
Restrictive cardiomyopathy 2 (8%)
Postoperative CHD 6 (22%)
Single ventricle s/p Fontan 1
Single ventricle s/p Glenn 1
Aortic stenosis s/p Ross operation 1
Anomalous LCA origin from PA s/p reimplantation 1
CCTGA s/p tricuspid valve replacement 1
CAVC s/p biventricular repair and mitral valve replacement 1
Diagnoses
Apostolopoulou SC, et al. Pediatr Cardiol. 2018 Oct;39(7):1315-1322
Diagnosis –Age at initiation
0
2
4
6
8
10
12
14
Myocarditis Dilated CM Restrictive CM CHD
Diagnoses
22%
48%
8%
22%
Nu
mb
er o
f p
atie
nts
0
2
4
6
8
10
12
0-1yo 1-5yo 5-10yo 10-18yo >18yo
Age at initiation of AI/LS
Nu
mb
er o
f p
atie
nts
22%
15%
37%
7%
19%
Apostolopoulou SC, et al. Pediatr Cardiol. 2018 Oct;39(7):1315-1322
Results – Summary (27 pts)
• Median F/U 2.1 (0.3-21.3) years
• 4 pts (2 DCM, 2 RCM): prolonged hospitalization and death after 0.8-2.1 years (mortality 15%)
• 6 pts (22%): heart transplantation after 0.3-2.3 years
• 17 pts stable for 4mos to 3.4 yrs
• WHO class I-II, good QoL, good social life, attending school, playground
• AI weaned and discontinued in- 6 improved myocarditis pts after 1.2 (0.4-2.3) yrs - 2 CM pts after 0.7 and 3.7 years (still on LS infusions)- 1 CM pt with LVAD and was transplanted 3.5 yrs later
Apostolopoulou SC, et al. Pediatr Cardiol. 2018 Oct;39(7):1315-1322
AI as bridge to recovery
• 6 patients
• 3 Parvo B19
• 4 pts received:
- AI for 0.3-1.3 yrs
- LS for 0.3-1.2 yrs
• 2 pts received:
- only LS for 1.1-2.3 yrs
• Post discontinuation:
stable without HF or
deterioration and LVEF >
60% over 2.8 (0.6-3.4) yrs0 5 10 15 20 25
6
5
4
3
2
1
AI
LS
Bridge to recovery
Pat
ien
ts
Months
Apostolopoulou SC, et al. Pediatr Cardiol. 2018 Oct;39(7):1315-1322
AI and/or LS as bridge to recovery
1 mo after discontinuation of HI,
SF 33%
Initial SF 16% 9 mos HI, SF 26%
2.7 yrs after discontinuation of HI,
SF 40%
6 mos HI, SF 14%
1 yr after discontinuation of HI,
SF 33%
Apostolopoulou SC, et al. Pediatr Cardiol. 2018 Oct;39(7):1315-1322
Home inotropes as bridge to recovery
SF (%) versus time (months)
0
10
20
30
40
50
0m 3m 6m 12m 24m 30m
25
35
45
55
0m 3m 6m 12m 24m 30m
LVEDD (mm) versus time (mos)
• 3 parvovirus myocarditis patients with full recovery
• All needed both IV inotropes and levosimendan initially
• One agent discontinued after months, but remodeling and recovery
required treatment for 1 year
=Stop inotropes
=Stop levosimendan
SF (%)LVEDD
Apostolopoulou SC, et al. Pediatr Cardiol. 2018 Oct;39(7):1315-1322
AI and/or LS as mainstay therapy
• 4 deaths after 0.8-2.1 years of AI
• 11 pts stable WHO class II: 7 pts AI+LS for 0.3-3.7 yrs / 4 pts only LS for 0.5-4.2yrs
• 3 discontinuations (1 LVAD, 2 CM still on LS)
0 5 10 15 20 25 30 35 40 45 50
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
AI LS
Mainstay therapy
: deaths
Pat
ien
ts
Months
Apostolopoulou SC, et al. Pediatr Cardiol. 2018 Oct;39(7):1315-1322
AI and/or LS as mainstay therapy
2 yrs home inotropes
LVEDD 45mm, SF 21%, 2+ MR
3.4 yrs on HI, monthly Simdax
LVEDD 47mm, SF 21%, 2+ MR
Attempt at weaning
Start inotropes in hospital, home
after 1 month
LVEDD 48mm, SF 18%, 3-4+MR
AI and/or LS until Transplant
• 6 patients, dilated CM, AI 3-27 mos, levosimendan 7-24 mos
• Pts 1,2: heart transplant on AI (F/U 21 years post transplant)
• Pt 3: abrupt stop inotropes→shock→LVAD→Heart Tx (F/U 2 yrs)
• Pt 4, 5, 6: abrupt stop inotropes→shock→ECMO→Death
0 5 10 15 20 25 30
6
5
4
3
2
1
AI LS
Bridge to transplant
*
*
*
: deaths
Months
Pat
ien
ts
Apostolopoulou SC, et al. Pediatr Cardiol. 2018 Oct;39(7):1315-1322
AI in PH due to LV dysfunction
44
62
28 28
1.6 1.7
9.8
19.8
32
26
20
14
3.6 3 2.84
0
10
20
30
40
50
60
Pt 1 Pt 2 Pt 1 Pt 2 Pt 1 Pt 2 Pt 1 Pt 2
Mean PAP(mmHg) PCWP(mmHg) CI (L/min/m2) PVRI (Wood U)
Baseline
After AI
Pulmonary hypertension in HF
Hem
od
ynam
icva
riab
les
bef
ore
an
d a
fter
AI
Both patients underwent successful heart transplantation at our
institution and remain stable over 21 years follow up
Apostolopoulou SC, et al. Pediatr Cardiol. 2018 Oct;39(7):1315-1322
Ambulatory inotropes - Quality of life
• Diagnosis DCM 2.9yo
• Stabilization only on IV
Dob/Mil at 3.1 yo
• AI for 3.7 yrs
• Monthly LS 3.9 yrs
• Now 8yo
• 3rd grade at school
• Happy, playful with 4yo
brother
• Successful weaning of AI last
year, remained on LS, she
went swimming last summer!
Complications - Safety
• 4 line infections, in 3 patients:- 3 → IV antibiotics for 2 weeks with subsequent negative
cultures for weeks- 1 → 2nd infection 6 mos after the 1st → inadequate response to
IV antibiotics → catheter removal and reinsertion later
• 4 catheter dislodgements in infants → reinsertion
• No reports of pump malfunction or emergent hospital admissions apart from the line infections
• No neurologic, bleeding or thromboembolic events
• No sudden deaths, no defibrillator discharge
Apostolopoulou SC, et al. Pediatr Cardiol. 2018 Oct;39(7):1315-1322
Heart or Heart-Lung Transplantation
• No pediatric heart transplant program in Greece
• Adult heart transplant program in Greece considers patients > 12 yo or small adult size
• Donor shortage (6-10 per year for Greece)
• No heart-lung or lung transplant program in Greece (for pulmonary hypertension pts)
• Difficult acceptance of candidates in foreign programs
• CHD issues: prior operations, guarded results, difficult acceptance of candidates in foreign transplant programs
Apostolopoulou SC, et al. Pediatr Cardiol. 2018 Oct;39(7):1315-1322
Conclusions-Long-term AI and/or LS
• Feasible, safe, with few complications in pediatric pts with intractable CHF, even in infants
• Good QoL considering severity of disease
• Mainstay therapy in absence of transplant option
• No sudden deaths or significant arrhythmias (nonischemicetiology)
• Allows remodeling and possible recovery in myocarditis, which may take up to 1 year
• Improves PH to allow possible heart transplant
• Provides time to allow transfer in foreign Pediatric Transplant Program or allow growth to permit transplant in local Adult Transplant Program
Apostolopoulou SC, et al. Pediatr Cardiol. 2018 Oct;39(7):1315-1322
There is no conflict of interest